These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24154780)

  • 1. New urate-lowering therapies in Aotearoa New Zealand: a response to Dr Lance Gravatt's letter on benzbromarone hepatotoxicity.
    Dalbeth N; Gow P; Stamp L; Merriman T; Stuart R; Winnard D; Lindsay K;
    N Z Med J; 2013 Sep; 126(1382):120-3. PubMed ID: 24154780
    [No Abstract]   [Full Text] [Related]  

  • 2. Benzbromarone: availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt onbenzbromarone).
    Day R; Lee H; Graham G; Williams K
    N Z Med J; 2013 Sep; 126(1382):124-6. PubMed ID: 24154781
    [No Abstract]   [Full Text] [Related]  

  • 3. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice.
    Winnard D; Wright C; Jackson G; Gow P; Kerr A; McLachlan A; Orr-Walker B; Dalbeth N
    N Z Med J; 2012 Jan; 126(1368):53-64. PubMed ID: 23385835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gout--is adequate attention devoted to preventing haemorrhagic risk when benzbromarone is administered with warfarin?
    Gravatt L
    N Z Med J; 2013 Sep; 126(1382):116-7. PubMed ID: 24154778
    [No Abstract]   [Full Text] [Related]  

  • 6. Decreased incidence of diabetes in patients with gout using benzbromarone.
    Niu SW; Chang KT; Ta A; Chang YH; Kuo IC; Hung CC; Chiu YW; Hwang SJ; Lin SF; Lin HY
    Rheumatology (Oxford); 2018 Sep; 57(9):1574-1582. PubMed ID: 29796661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular epidemiology in New Zealand and the Pacific.
    Prior IA
    N Z Med J; 1974 Sep; 80(524):245-52. PubMed ID: 4531554
    [No Abstract]   [Full Text] [Related]  

  • 8. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers.
    Jackson G; Dalbeth N; Te Karu L; Winnard D; Gow P; Gerard C; Minko N
    N Z Med J; 2014 Oct; 127(1404):37-47. PubMed ID: 25331310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzbromarone therapy in management of refractory gout.
    Kumar S; Ng J; Gow P
    N Z Med J; 2005 Jun; 118(1217):U1528. PubMed ID: 15980902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National prevalence of gout derived from administrative health data in Aotearoa New Zealand.
    Winnard D; Wright C; Taylor WJ; Jackson G; Te Karu L; Gow PJ; Arroll B; Thornley S; Gribben B; Dalbeth N
    Rheumatology (Oxford); 2012 May; 51(5):901-9. PubMed ID: 22253023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperuricemia, gout and cardiovascular diseases].
    Murray K; Burkard T
    Ther Umsch; 2016; 73(3):141-6. PubMed ID: 27008446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.
    Bardin T; Richette P
    BMC Med; 2017 Jul; 15(1):123. PubMed ID: 28669352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009.
    Robinson PC; Merriman TR; Herbison P; Highton J
    Rheumatology (Oxford); 2013 Jan; 52(1):118-26. PubMed ID: 22989425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
    Kydd AS; Seth R; Buchbinder R; Falzon L; Edwards CJ; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():33-41. PubMed ID: 25180126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.